📊 NXGLW Key Takeaways
Is Nexgel, Inc.. (NXGLW) a Good Investment?
NEXGEL faces a severe liquidity crisis with only $317K cash against negative $1.4M annual free cash flow, providing less than 3 months of operational runway. The company is unprofitable with stagnant revenue growth, persistent operating losses of $3.4M on $11.4M revenue, and negative operating cash flow, indicating fundamental business challenges in the medical device market with no clear path to profitability.
Why Buy Nexgel, Inc.. Stock? NXGLW Key Strengths
- Acceptable gross margin of 39.5% demonstrates product profitability at gross level
- Moderate debt burden with debt-to-equity ratio of 0.13x provides some balance sheet flexibility
- EPS improvement of 24% year-over-year shows marginal operational progress despite losses
NXGLW Stock Risks: Nexgel, Inc.. Investment Risks
- Critical cash position of $317K with negative $1.4M FCF creates imminent solvency risk with less than 3 months runway
- Quick ratio of 0.75x and negative operating cash flow indicate severe liquidity stress and inability to meet short-term obligations
- Zero revenue growth combined with persistent $3.4M operating losses suggests fundamental market rejection or operational dysfunction
- Negative ROE of -67.3% and ROA of -28.7% indicate severe value destruction for shareholders and inefficient asset utilization
- No insider activity in past 90 days demonstrates complete lack of management conviction in the turnaround
Key Metrics to Watch
- Cash balance and burn rate - potential bankruptcy trigger if cash falls below $100K
- Operating cash flow return to positive - critical inflection point for viability
- Revenue growth acceleration - current 0% growth unsustainable for surgical device company
Nexgel, Inc.. (NXGLW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Nexgel, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
NXGLW Profit Margin, ROE & Profitability Analysis
NXGLW vs Healthcare Sector: How Nexgel, Inc.. Compares
How Nexgel, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nexgel, Inc.. Stock Overvalued? NXGLW Valuation Analysis 2026
Based on fundamental analysis, Nexgel, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nexgel, Inc.. Balance Sheet: NXGLW Debt, Cash & Liquidity
NXGLW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nexgel, Inc..'s revenue has grown significantly by 179% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.50 indicates the company is currently unprofitable.
NXGLW Revenue Growth, EPS Growth & YoY Performance
NXGLW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.9M | -$653.0K | $-0.08 |
| Q2 2025 | $1.4M | -$665.0K | $-0.09 |
| Q1 2025 | $1.3M | -$712.0K | $-0.09 |
| Q3 2024 | $1.2M | -$550.0K | $-0.10 |
| Q2 2024 | $1.2M | -$695.0K | $-0.12 |
| Q1 2024 | $620.0K | -$814.0K | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nexgel, Inc.. Dividends, Buybacks & Capital Allocation
NXGLW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nexgel, Inc.. (CIK: 0001468929)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NXGLW
What is the AI rating for NXGLW?
Nexgel, Inc.. (NXGLW) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NXGLW's key strengths?
Claude: Acceptable gross margin of 39.5% demonstrates product profitability at gross level. Moderate debt burden with debt-to-equity ratio of 0.13x provides some balance sheet flexibility.
What are the risks of investing in NXGLW?
Claude: Critical cash position of $317K with negative $1.4M FCF creates imminent solvency risk with less than 3 months runway. Quick ratio of 0.75x and negative operating cash flow indicate severe liquidity stress and inability to meet short-term obligations.
What is NXGLW's revenue and growth?
Nexgel, Inc.. reported revenue of $11.4M.
Does NXGLW pay dividends?
Nexgel, Inc.. does not currently pay dividends.
Where can I find NXGLW SEC filings?
Official SEC filings for Nexgel, Inc.. (CIK: 0001468929) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NXGLW's EPS?
Nexgel, Inc.. has a diluted EPS of $-0.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NXGLW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nexgel, Inc.. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NXGLW stock overvalued or undervalued?
Valuation metrics for NXGLW: ROE of -67.3% (sector avg: 15%), net margin of -26.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NXGLW stock in 2026?
Our dual AI analysis gives Nexgel, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NXGLW's free cash flow?
Nexgel, Inc..'s operating cash flow is $-1.3M, with capital expenditures of $68.0K. FCF margin is -12.1%.
How does NXGLW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -26.3% (avg: 12%), ROE -67.3% (avg: 15%), current ratio 1.47 (avg: 2).